Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Novavax Inc (NVAX)

Novavax Inc (NVAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Novavax Inc 700 Quince Orchard Road GAITHERSBURG MD 20878 USA

www.novavax.com P: 240-268-2000

Description:

Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple studies.'Novavax developed its own coronavirus vaccine NVX-CoV2373. The company is currently marketing two versions of NVX-CoV2373, one marketed in partnership with the Serum Institute of India under the trade name Covovax and another version produced by Novavax and marketed under the trade name Nuvaxovid.'Novavax developed NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix M adjuvant for senior patients aged 65 years and above.'ResVax a respiratory syncytial virus vaccine is being developed to protect infants by immunizing mothers against the disease. Novavax is discussing the opportunity to bring ResVax to the market globally with the help of commercial partners.

Key Statistics

Overview:

Market Capitalization, $K 544,417
Enterprise Value, $K -34,513
Shares Outstanding, K 139,953
Annual Sales, $ 983,710 K
Annual Net Income, $ -545,060 K
Last Quarter Sales, $ 291,340 K
Last Quarter Net Income, $ -178,390 K
EBIT, $ -566,510 K
EBITDA, $ -525,280 K
60-Month Beta 1.59
% of Insider Shareholders 0.90%
% of Institutional Shareholders 53.04%
Float, K 138,693
% Float 99.10%
Short Volume Ratio 0.58

Growth:

1-Year Return -58.17%
3-Year Return -98.13%
5-Year Return -60.34%
5-Year Revenue Growth 2,768.80%
5-Year Earnings Growth 45.90%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.44 on 02/28/24
Latest Earnings Date 05/14/24
Earnings Per Share ttm -5.53
EPS Growth vs. Prev Qtr -14.29%
EPS Growth vs. Prev Year 36.84%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 05/10/19

NVAX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -32.63%
Profit Margin % -55.41%
Debt/Equity 0.00
Price/Sales 0.57
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -6.04
Interest Coverage -36.66
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar